Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Core Points - Royalty Pharma plc has appointed Dr. Ted W. Love as Lead Independent Director, a role he will assume while continuing to chair the Nominating and Corporate Governance Committee [1][2] - Dr. Love brings extensive biopharma experience, having served in various leadership roles, including as President and CEO of Global Blood Therapeutics and as a board member of Gilead Sciences [2][3] - Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry, with a portfolio that includes royalties on over 35 commercial products [4] Company Overview - Founded in 1996, Royalty Pharma collaborates with a range of innovators from academic institutions to leading global pharmaceutical companies [4] - The company funds innovation both directly by co-funding late-stage clinical trials and indirectly by acquiring existing royalties from original innovators [4] - Current portfolio includes royalties from notable therapies such as Vertex's Trikafta, Johnson & Johnson's Tremfya, and Gilead's Trodelvy, among others [4]